Acacia (Gum Arabic): A Comprehensive Reference
1. Identity and Botanical Description
Nomenclature and Taxonomy
Gum arabic (also known as gum acacia, gum sudani, Senegal gum, and by other names) is a tree gum exuded by two species in the Acacia genus in its sensu lato (broad sense) pre-2005 meaning: Senegalia senegal and Vachellia seyal. Following a major 2005 reclassification of the genus, the primary source species underwent nomenclatural revision: Senegalia senegal (also known as Acacia senegal) is a small thorny deciduous tree from the genus Senegalia, which is known by several common names, including gum acacia, gum arabic tree, Sudan gum, and Sudan gum arabic.
It is also known as Gum Acacia, Kordofan Gum, Gum Senegal, Acacia Vera, Gummi Africanum, Gummae Mimosae, kher, Sudan Gum Arabic, Somali Gum, Yellow Thorn, Mogadore Gum, Indian Gum, and Australian Gum. Gum arabic was defined by the 31st Codex Committee for Food Additives as the dried exudate from the trunks and branches of Acacia senegal or Vachellia (Acacia) seyal in the family Fabaceae (Leguminosae).
With more than 1,200 species, the genus Acacia is the second largest in the Leguminosae (Fabaceae) family. In pharmacopeial and regulatory contexts, however, the term "acacia" as a dietary supplement or food additive refers almost exclusively to the gum exudate derived from Senegalia senegal (A. senegal) and, secondarily, Vachellia seyal (A. seyal).
Botanical Description
Senegalia senegal is a small thorny deciduous tree native to semi-desert regions of Sub-Saharan Africa, as well as Oman, Pakistan, and west coastal India. It grows to a height of 5–12 metres, with a trunk up to 30 cm in diameter. The acacia tree (A. senegal; synonym Acacia verek Guill et Perr.) is a thorny, scraggly tree that grows approximately 4.5 m in height, is most abundant in regions of Africa, especially in the Republic of Sudan, and has a distinguishing feature: the presence of triple spines at the branchlet base.
Geographic Origin and Commercial Production
The gum is harvested commercially from wild trees, mostly in Sudan (about 70% of the global supply) and throughout the Sahel, from Senegal to Somalia. Gum arabic is produced mainly in the Sahel area of Africa, the region stretching from Senegal on the Atlantic coast, through parts of Mauritania, Mali, Burkina Faso, Niger, Nigeria, Chad, and Sudan to Eritrea on the Red Sea coast. In East Africa, it is produced in Kenya, Somalia, and Tanzania.
Sudan is the source of the world's highest quality gum arabic, known locally as hashab gum, in contrast to the related, but inferior, gum arabic from red acacia, known as talah gum. Acacia senegal accounts for approximately 80% of the production of gum arabic, with Acacia seyal, Acacia laeta, Acacia camplylacantha, and Acacia drepanolobium supplying the remaining 20%.
Harvesting and Preparation
Sap is extracted from acacia trees by cutting incisions in their bark that allow the liquid to seep out. After that, the sap turns into gum. During the sap harvesting season, high temperatures, low humidity, and little rainfall encourage the sap to dry and harden quickly once it has seeped out from cuts in the tree bark. It is then harvested. The gum is drained from cuts in the bark, and an individual tree will yield 200 to 300 grams (7 to 10 oz).
Common Forms and Preparations
Gum arabic is a complex mixture of glycoproteins and polysaccharides, predominantly polymers of arabinose and galactose. It is soluble in water, edible, and used primarily in the food industry and soft drink industry as a stabilizer, with E number E414. As a dietary supplement, it is marketed in powder form, as a dissolved liquid, and in capsules or sachets. Organic Acacia Fiber Powder is a dietary fiber made from the gum of the Acacia tree; it is pure, natural, and soluble. The monograph in the National Formulary (USP-NF) is titled "Acacia" and defined as the "dried gummy exudate from the stems and branches of Acacia senegal or of other related African species of Acacia."
Its distinct qualities and water solubility make it useful across a range of sectors, including pharmaceuticals, food and beverages, and personal care industries. It is an ingredient in processed meals, soft drinks, and confections; a thickening agent in chewing gums; a binder in watercolour paints; an additive in ceramic glazes; and an adhesive in the rolling papers used in cigarettes.
2. Traditional and Historical Use
Ancient Egypt and the Near East
Gum arabic's first recorded use dates back to 2000 BC, when ancient Egyptians employed it in foodstuffs, hieroglyphic paints, and mummification ointments. Humans have in fact used gum arabic for thousands of years; one of its earliest known uses was as an embalming agent in ancient Egypt. The Egyptians used the material as a glue and as a pain-reliever base. Arabic physicians treated a wide variety of ailments with the gum, resulting in its current name.
Ancient Greek writings mention its use to relieve discomfort of blisters, burns, and stop nosebleeds. Later periods found artists utilizing it to bind pigments and in ink. More modern occurrences found it in glue, as part of textile manufacturing, and in early photographic prints.
Traditional African and Middle Eastern Medicine
Gum arabic has been used for at least 4,000 years by local people for preparation in food, in human and veterinary medicine, in crafts, and as a cosmetic. The traditional practice in African and Middle Eastern countries uses this gum as medicine. Traditional use of acacia gum is to treat stomach disease. GA has historically been used for chronic renal disease, stomach pain, and other disorders.
The name "gum Arabic" was used in the Middle East at least as early as the 9th century. Gum arabic first found its way to Europe via Arabic ports and retained its name of origin.
Pharmacopeial History in the West
The first edition of the United States Pharmacopeia (USP), published in 1820, listed Acaciae gummi (acacia gum, called gum arabic). During the Civil War era in the 1860s, imported gum arabic (S. senegal) reportedly was not readily available in the supply chain, and slippery elm (Ulmus rubra, Ulmaceae) inner bark was an alternative for physicians and pharmacists.
3. Key Constituents and Active Compounds
Primary Macromolecular Composition
Gum arabic is a complex mixture of glycoproteins and polysaccharides, predominantly polymers of arabinose and galactose. Chemically, gum arabic is a polysaccharide and hydrocolloid substance (a substance that becomes a gel in water); its exact chemical composition differs depending on the acacia species from which it is harvested and possibly the conditions under which the tree is grown.
Carbohydrate analysis has indicated that the components of this gum from the different sources all have a highly branched structure consisting of a β-1,3-linked d-galactose core with extensive branching through 3- and 6-linked galactose and 3-linked arabinose.
Molecular Fractions
Chromatographic fractionation has consistently identified three main molecular components of acacia gum: Three main molecular fractions are isolated after hydrophobic interaction chromatography (HIC), and biochemical analyses confirm the presence of an arabinogalactan-peptide (FI), an arabinogalactan-protein (FII), and a glycoprotein (FIII) fraction.
- Arabinogalactan (AG) fraction: The main component is the arabinogalactan (AG) fraction that represents around 90% of the gum, containing less than 1% protein.
- Arabinogalactan-protein (AGP) fraction: The second major component (~10 wt% of the total) consists of a higher molecular weight arabinogalactan-protein (AGP) fraction and contains ~10% protein.
- Glycoprotein (GP) fraction: The smallest component (~1% of the total) consists of a glycoprotein (GP).
The major molecular fraction (F1) accounting for ~88% of the total acacia gum mass is an arabinogalactan peptide. The AGP structure of gum arabic adopts a very compact conformation in solution due to the attachment of short arabinoside side chains and much larger blocks of carbohydrate to the polypeptidic backbone.
Secondary Metabolites
Studies have shown that Acacia possesses several secondary metabolites, including amines, cyanogenic glycosides, flavonoids, alkaloids, seed oils, cyclitols, fluoroacetate, gums, non-protein amino acids, diterpenes, fatty acids, terpenes, hydrolyzable tannins, and condensed tannins. These activities were reported after biological experiments using the total content (not pure individual compounds) of gum arabic, which contains mainly macro-polysaccharide contents (more than 80% w/w) and a small amount of protein (1–3.5% w/w) in addition to traces of other phytoconstituents, e.g., flavonoids, saponins, polyphenolic compounds/tannins, and others.
Established Mechanisms of Action
The pharmacological activities of gum arabic are attributed mainly to the polysaccharide contents; however, the biological activities of other phytoconstituents and at least their synergistic effects cannot be neglected, especially since there are no confirmed results of the direct relation between specific Acacia phytoconstituents and their direct biological activities.
Prebiotic fermentation and short-chain fatty acid (SCFA) production: Gum arabic fermentation by colonic bacteria increases serum butyrate concentrations, and it is therefore considered a prebiotic agent. Gum arabic has anti-inflammatory activity through its derivative butyrate.
Antioxidant mechanisms: The antioxidative mechanism of GA involves its impact on the Nrf2 signaling pathway, which increases antioxidant enzymes such as superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) in renal tissues.
Anti-inflammatory pathway: GA has also been shown to inhibit the activation of the NF-κB pathway.
Physical properties relevant to satiety and glycemia: Having exceptionally low viscosity, acacia gum is the best source of soluble dietary fiber because it can boost fiber levels in foods or beverages without modifying the final viscosity of food products. It is highly soluble in water. The compounds in Acacia species exhibit a wide range of pharmaceutical applications such as anti-inflammatory, antioxidant, antidiarrheal, antidiabetic, anticancer, antiviral, and liver protective effects.
4. Scientific Evidence by Area of Use
4.1 Gastrointestinal Health and Prebiotic Effects
Summary: The prebiotic potential of acacia gum is the best-substantiated area of clinical research, supported by both in-vitro fermentation models and randomized human trials.
In-vitro evidence: Commercially available acacia gum from Acacia senegal and Acacia seyal was investigated in a pH-controlled in vitro colon model inoculated with human fecal microbiota. Fermentation samples at 0, 6, 12, and 24 h were subjected to short-chain fatty acid (SCFA) analysis and bacterial enumeration. Results showed that acacia gum significantly promotes Bifidobacteria proliferation similar to fructo-oligosaccharides (FOS) while inhibiting the Clostridium histolyticum group, commonly associated with gut dysbiosis.
Human clinical evidence: A randomized, double-blinded, double-controlled trial in healthy human volunteers confirmed the prebiotic efficacy of GA, showing significant increases in bifidobacteria and lactobacilli. Research has indicated that soluble fiber in the diet can aid in improving bowel regularity. Acacia powder also exhibits tremendous prebiotic potential, as it is able to support healthy intestinal flora. Since it reduces fermentation and decreases bloating and gas problems, acacia powder is well tolerated and can be taken on a daily basis.
Limitations: Various human clinical trials have supported the health claims of GA consumption; however, these are not widely accepted in clinical practice due to the lack of mechanistic insight. Individual trial populations have often been relatively small and drawn primarily from Sudanese or Middle Eastern cohorts.
4.2 Satiety, Appetite Regulation, and Body Weight
Summary: Randomized controlled trials in healthy adults and metabolic-syndrome-risk populations support a modest but consistent satiety effect, with limited but suggestive evidence for body composition change.
Key human trial: Acacia gum (AG) is a non-viscous soluble fiber that is easily incorporated into beverages and foods. To determine its physiological effects in healthy human subjects, researchers fed 0, 20, and 40 g of acacia gum in orange juice along with a bagel and cream cheese after a 12-hour fast, and compared satiety, glycemic response, gastrointestinal tolerance, and food intake among treatments. Subjects (n = 48) reported less hunger and greater fullness at 15 min (p = 0.019 and 0.003, respectively) and 240 min (p = 0.036 and 0.05, respectively) after breakfast with the 40 g fiber treatment.
GA was found to have a positive effect on satiety and appetite reduction. Subjects reported a decrease in caloric intake and an increase in their satiety following consumption of GA. Furthermore, when studying the effects of ingesting GA on adults who were at high risk of developing metabolic syndrome, it was found that study subjects had reduced systolic and diastolic blood pressure, fat-free body mass, appetite, and fasting plasma glucose, along with an increased dietary fiber intake.
Metabolic syndrome RCT: In a controlled, randomized, single-blind, parallel-design study, an intervention group received 20 g of GA-AS daily for 12 weeks compared to a control group receiving a daily placebo containing 1 g of pectin. After 12 weeks, participants receiving the GA showed significant decreases in systolic and diastolic blood pressure, fat-free body mass, energy and carbohydrate consumption, and fasting plasma glucose, as well as increased intake of dietary fiber. They also reported improvements in self-perceived bloating and quality of bowel movements, as well as a decreased appetite score. These results suggest that GA could be a safe and beneficial adjunct to other treatments for those with, or at risk of, metabolic syndrome.
Evidence strength: Moderate. Effects are consistent across multiple randomized trials, but individual study sample sizes are modest and dose standardization varies.
4.3 Glycemic Control and Diabetes
Summary: Both clinical and animal evidence exists, though human trials are variable in their endpoints and results, and evidence remains preliminary.
Acacia polyphenol (AP) trial: A clinical study investigated the effects of acacia polyphenol (AP) on glucose and insulin responses to an oral glucose tolerance test (OGTT) in non-diabetic subjects with impaired glucose tolerance (IGT). A randomized, double-blind, placebo-controlled trial was conducted in a total of 34 enrolled subjects. Subjects were randomly assigned to the AP-containing dietary supplement (in a daily dose of 250 mg as AP; n=17) or placebo (n=17). Compared with the baseline, plasma glucose and insulin levels at 90 and/or 120 min, as well as the total area under the curve values during the OGTT for glucose and insulin, were significantly reduced in the AP group, but not in the placebo group, after intervention for 8 weeks.
PCOS pilot study: Gum arabic (GA) is well-known for its prebiotic and antioxidant effects. A clinical trial assessed the changes in hormonal and metabolic profiles in PCOS patients after the ingestion of gum arabic, conducted on fifteen patients suffering from PCOS, with a mean age of 27.8 years.
Postprandial glucose: In the University of Minnesota crossover RCT (n=48), at a concentration of 20 g, the fiber reduced postprandial serum glucose levels and improved satiety in human subjects.
Evidence strength: Preliminary to moderate. Results from small randomized trials indicate reductions in postprandial and fasting glucose; however, trial populations have been small, methodologies differ, and the comparative effectiveness against standard treatments has not been established.
4.4 Lipid Profile and Cardiovascular Risk
Summary: A 2023 systematic review of clinical trials found effects on lipid parameters; individual study results are mixed, and evidence quality is generally low to moderate.
Twenty-nine papers were included in a systematic review of clinical trials. The results showed that ingestion of GA altered lipid profiles, renal profiles, plaque, gingival scores, biochemical parameters, blood pressure, inflammatory markers, and adiposity. GA exhibited anti-inflammatory, prebiotic, and antibacterial properties.
The databases used included PubMed, Scopus, and Cochrane, searched using the keywords ("Gum Arabic" OR "Acacia senegal" OR "Acacia seyal" OR "Gum Acacia" OR "Acacia Arabica") AND ("Clinical Trial" OR "Randomized Controlled Trial" OR "Randomized Clinical Trial").
GA has been used in clinical research to treat sickle cell anemia, rheumatoid arthritis, metabolic disorders, periodontitis, gastrointestinal conditions, and kidney diseases.
Evidence strength: Low to moderate. Most individual trials show some lipid-modifying effects, but are limited by small sample sizes and varying methodological quality.
4.5 Renal Health and Chronic Kidney Disease (CKD)
Summary: This is one of the most active clinical research areas for gum arabic, reflecting its traditional use in renal conditions. Animal studies show clear antioxidant and anti-inflammatory benefits; human trials are promising but methodologically limited.
Gum arabic has demonstrated antioxidative and anti-inflammatory properties that may benefit renal function, as shown in animal studies. Clinical trials suggest improvements in renal biomarkers, though these are limited by scope and methodology. While promising, the clinical application of gum arabic requires cautious interpretation due to gaps in understanding its mechanisms of action. Gum arabic shows potential as an adjunct treatment for CKD, reflecting both traditional use and preliminary scientific evidence.
Animal mechanistic data: In an adenine-induced CKD rat model, Ali et al. (2013) and Al Za'abi et al. (2015) demonstrated that GA reduces markers of inflammation and oxidative stress, enhances antioxidant capacity, and improves renal function.
Haemodialysis clinical trial: Forty end-stage renal failure (ESRF) patients aged 18–80 years who were on regular haemodialysis were recruited in a single-arm non-randomized open-label clinical trial. The study assessed oxidative stress markers including malondialdehyde (MDA) and C-reactive protein (CRP). Gum arabic has been claimed to act as an antioxidant and anti-inflammatory agent in experimental studies and clinical trials.
Clinical trials suggest improvements in renal biomarkers, though these are limited by scope and methodology. While promising, the clinical application of gum arabic requires cautious interpretation due to gaps in understanding its mechanisms of action. Gum arabic shows potential as an adjunct treatment for CKD, reflecting both traditional use and preliminary scientific evidence.
Evidence strength: Preliminary. Animal evidence is consistent; human clinical trials in CKD and haemodialysis patients show improvements in biomarkers but are largely non-randomized, small-scale, or single-arm.
4.6 Inflammation and Rheumatoid Arthritis
Summary: One Phase II clinical trial has examined gum arabic in rheumatoid arthritis patients; the evidence is very preliminary.
Rheumatoid arthritis (RA) is an autoimmune inflammatory disease that attacks the synovium of the joints. Both TNF-α and interleukin-1 play crucial roles in the pathogenesis of RA. Gum arabic is a gummy exudate from the Acacia senegal tree. A Phase II clinical trial in which 40 patients aged 18 to 70 years were enrolled. Patients received 30 g/day GA for 12 weeks. TNF-α, ESR, and complete blood count were measured and DAS-28 was calculated before and after regular GA consumption.
Evidence strength: Very preliminary. A single Phase II trial without a placebo-controlled design; results require replication in larger, adequately powered RCTs.
4.7 Oral Health
Summary: There is a randomized controlled trial of gum arabic in gingivitis with measured clinical endpoints.
Further studies have proven the efficacy of acacia gum in oral diseases, wound management, and stoma care, where its anti-inflammatory and antibacterial properties are useful. A randomized controlled trial examined the effect of gum arabic on plaque-induced gingivitis (Gafar et al., 2022, Saudi Dental Journal).
Evidence strength: Preliminary. Very few trials exist; mechanistic plausibility rests on antibacterial properties documented for the genus, but clinical evidence base is minimal.
4.8 Sickle Cell Anemia
Bilirubin and serum ALT were reduced among patients with sickle cell disease (N=47) given gum arabic 30 g daily in a 12-week single-arm study. The systematic review by Al-Jubori et al. (2023) noted that GA has been used in clinical research to treat sickle cell anemia, though the evidence base remains very small and trial designs are limited.
Evidence strength: Very preliminary. Single-arm study with no comparator; requires placebo-controlled replication.
5. Body Systems Associated With Acacia Supplementation
- Gastrointestinal system: Prebiotic effects on gut microbiota composition (bifidobacteria, lactobacilli); improved bowel movement quality; SCFA production.
- Metabolic / endocrine system: Postprandial glucose attenuation; fasting glucose reduction in metabolic syndrome; modest effects on lipid profiles.
- Renal system: Antioxidant and anti-inflammatory effects relevant to CKD management; reduction of oxidative stress biomarkers in haemodialysis patients.
- Cardiovascular system: Blood pressure reduction documented in the metabolic syndrome RCT; lipid profile modification across multiple trials.
- Immune / inflammatory system: Inhibition of NF-κB; upregulation of Nrf2 antioxidant pathways; butyrate-mediated anti-inflammatory signaling.
- Oral cavity: Antibacterial properties tested against plaque-induced gingivitis.
6. Dosage Forms and Dosages Reported in Studies
Dosages across clinical studies vary considerably. The following are doses as reported in the cited studies:
- Several trials used gum arabic 30 g orally daily for 6 to 12 weeks for various indications.
- A Phase II trial in rheumatoid arthritis enrolled 40 patients aged 18 to 70 years; patients received 30 g/day GA for 12 weeks.
- A parallel-design RCT in metabolic-syndrome-risk adults used 20 g of GA-AS daily for 12 weeks.
- A randomized crossover trial in 48 healthy subjects tested 0, 20, and 40 g of acacia gum in orange juice along with a bagel and cream cheese after a 12-hour fast.
- A randomized, double-blind, placebo-controlled trial of acacia polyphenol used a daily dose of 250 mg (as AP) for 8 weeks in 34 subjects with impaired glucose tolerance.
- Human trials of AG doses up to 40 g/d for four weeks in healthy adults, 30 g/d for 6 weeks in university students and 3 months in adults with type 2 diabetes, and 25 g/d AG over 12 weeks in healthy adults and adults with diabetic nephropathy showed no adverse effects.
Clinical trials are generally lacking to provide standardized dosing recommendations. Further research is needed to standardize dosages, investigate long-term safety across diverse populations, and optimize the application of acacia gum for broader clinical use.
7. Safety Considerations and Drug Interactions
Regulatory Safety Status
Acacia is essentially nontoxic when ingested and is generally recognized as safe (GRAS). Gum arabic is generally recognized as safe (GRAS) by the FDA for use in foods.
Acacia gum was evaluated by JECFA in 1982 and 1990. Based on the lack of adverse effects in the available toxicity studies, an ADI "not specified" was allocated.
The EFSA Scientific Panel on Food Additives and Nutrient Sources (ANS) re-evaluated the safety of the additive acacia gum in 2017. In that opinion, the ANS Panel concluded that "Overall, the short-term and sub-chronic administration of oral doses up to 5000 mg acacia gum/kg bw per day to rats and 20,000 mg acacia gum/kg bw per day to mice, the highest doses tested, did not induce any biologically relevant adverse effects" and that "no carcinogenic effects were reported in carcinogenicity studies in mice and rats at the doses up to 7500 mg and 2500 mg acacia gum/kg bw per day, respectively, the highest doses tested."
Regarding genotoxicity, the EFSA ANS Panel assessed several in vitro and in vivo studies and concluded: "Overall, based on the data available, the Panel concluded that there is no concern with respect to the genotoxicity of acacia gum."
Adverse Effects Reported in Clinical Trials
Adverse effects reported in clinical trials included unfavorable sensation in the mouth, early morning nausea, mild diarrhea, and bloating. Subjects reported more bloating, flatulence, and GI rumbling on the 40 g fiber treatment compared to control, although values for GI tolerance were all low with AG treatment.
Allergy and Sensitization
Allergic reactions have been reported. Acacia gum is a potential dermal and respiratory sensitiser. Occupational exposure (e.g., inhalation of acacia gum powder) should be distinguished from normal dietary or supplemental ingestion.
Drug Interactions
Healthcare professionals should remain vigilant for the potential interactions between herbal medicines and prescribed drugs, especially when drugs with a narrow therapeutic index are used. The data show that acacia gum obtained from A. rabi reduced the absorption of drugs such as amoxicillin. The findings indicate that the coexistence of amoxicillin and gum arabic in the upper gastrointestinal tract resulted in a pharmacokinetic interaction that significantly decreased the absorption of amoxicillin.
Intravenous Administration
IV administration has been reported to cause renal and liver damage. This concern is specific to parenteral routes and does not apply to oral dietary supplementation.
Special Populations
Contraindications have not been formally identified for oral ingestion. However, information regarding safety and efficacy in pregnancy and lactation is lacking, and use should be avoided in these populations until further data are available.
Nomenclature Confusion
Acacia gum should not be confused with Acacia rigidula, acai, or cassie absolute (Acacia farnesiana). These are different plants with different effects. Acacia rigidula, in particular, has appeared in stimulant-type supplements under the name "acacia" and has a substantially different and more controversial pharmacological profile.
8. Evidence Summary and Limitations
Across all clinical research areas, the overall evidence base for gum arabic / acacia supplementation is best characterized as preliminary to moderate. The most robust clinical evidence supports prebiotic activity and satiety modulation. Effects on glycemia, blood pressure, and renal biomarkers are documented in randomized trials but are limited by small sample sizes, variable comparators, and predominantly single-region study populations (principally Sudan and the UAE).
More studies are needed regarding acacia gum's influence on cognitive performance, cholesterol levels, and nutrient absorption. GA has great potential as an alternative dietary fiber and is a functional food ingredient that exhibits therapeutic action; however, further research is needed to standardize dosages, investigate long-term safety across diverse populations, and optimize its application for broader clinical use.
The chemical composition of AG can change with its source, the age and place of the trees planted, rainfall intensity, and soil conditions. This natural variability poses a methodological challenge for standardization of clinical preparations and cross-study comparison.
References
Go back